It is well recognized that there are several programs within the United States that are capable of developing Quality Assurance programs for advanced technologies in radiation therapy. The goal of this application is to capitalize on the infrastructure and strengths of several Quality Assurance programs to develop a superstructure capable of developing Quality Assurance programs for advanced radiation technologies. The goal of this endeavor is to utilize the strengths of these defined programs in developing uniformity in quality assurance in advanced technologies throughout all participating Cooperative Groups. Specifically we propose to (1) develop quality assurance programs in three-dimensional conformal therapy that will be uniform to all Cooperative Groups who choose to participate in this program; (2) develop equivalent programs in brachytherapy to multiple body part sites to ensure uniformity and quality assurance and establish standards in normal tissue tolerance; (3) establish uniform guidelines in database interpretation that allow for all dose-volume histogram analysis for tumor volume and normal tissue to be housed in one database. We will also establish a program to house data in both tumor volume coverage and normal tissue coverage to enhance our knowledge about outcome analysis; (4) To provide appropriate storage and interpretation of diagnostic x-rays required for protocol analysis; (5) develop QA programs for further advanced technology treatment programs such as Intensity Modulated Radiation Therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA081647-02
Application #
6173854
Study Section
Special Emphasis Panel (ZCA1-OAA-5 (J1))
Program Officer
Deye, James
Project Start
1999-07-22
Project End
2002-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
2
Fiscal Year
2000
Total Cost
$808,654
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Faught, Austin M; Davidson, Scott E; Fontenot, Jonas et al. (2017) Development of a Monte Carlo multiple source model for inclusion in a dose calculation auditing tool. Med Phys 44:4943-4951
Olsen, Jeffrey R; Moughan, Jennifer; Myerson, Robert et al. (2017) Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. Int J Radiat Oncol Biol Phys 98:400-408
Taylor, Paige A; Kry, Stephen F; Followill, David S (2017) Pencil Beam Algorithms Are Unsuitable for Proton Dose Calculations in Lung. Int J Radiat Oncol Biol Phys 99:750-756
Taylor, Paige A; Kry, Stephen F; Alvarez, Paola et al. (2016) Results From the Imaging and Radiation Oncology Core Houston's Anthropomorphic Phantoms Used for Proton Therapy Clinical Trial Credentialing. Int J Radiat Oncol Biol Phys 95:242-8
Davidson, Scott E; Cui, Jing; Kry, Stephen et al. (2016) Modification and validation of an analytical source model for external beam radiotherapy Monte Carlo dose calculations. Med Phys 43:4842
Baumann, Brian C; Bosch, Walter R; Bahl, Amit et al. (2016) Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. Int J Radiat Oncol Biol Phys 96:78-86
Lee, W Robert; Dignam, James J; Amin, Mahul B et al. (2016) Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 34:2325-32
Bradley, Jeffrey D; Paulus, Rebecca; Komaki, Ritsuko et al. (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p Lancet Oncol 16:187-99
Hong, Theodore S; Moughan, Jennifer; Garofalo, Michael C et al. (2015) NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 93:29-36

Showing the most recent 10 out of 85 publications